Edwards Lifesciences (EW) reported Q4 adjusted earnings late Tuesday of $0.59 per diluted share, up from $0.55 a year earlier.
Analysts polled by FactSet expected $0.55.
Net sales for the quarter ended Dec. 31 rose to $1.39 billion from $1.27 billion a year earlier.
Analysts surveyed by FactSet expected $1.36 billion.
The company said it expects Q1 adjusted EPS of $0.58 to $0.64 on revenue of $1.35 billion to $1.43 billion. Analysts project EPS of $0.59 on revenue of $1.41 billion.
Edwards said its full-year guidance remains unchanged.
Shares of the company were up about 7% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。